RESP 1000

Drug Profile

RESP 1000

Alternative Names: RESP-1000

Latest Information Update: 02 Aug 2016

Price : $50

At a glance

  • Originator Respiratorius
  • Class Antiasthmatics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Asthma; Chronic obstructive pulmonary disease

Highest Development Phases

  • Preclinical Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 02 Aug 2016 Preclinical trials in Chronic obstructive pulmonary disease in Sweden (unspecified route)
  • 02 Aug 2016 Preclinical trials in Asthma in Sweden (unspecified route)
  • 02 Aug 2016 RESP 1000 is available for licensing as of 02 Aug 2016. http://www.respiratorius.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top